Mission Therapeutics

Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after MJFF awarded Mission preclinical research grants in 2017 and 2021, and first with Parkinson’s UK Comes as promising early data from healthy volunteers show MTX325...

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces the start of a phase I first-in-human clinical trial of MTX325, its potential disease-modifying...

Mission Therapeutics Appoints Colin Goddard as Chairman

CAMBRIDGE, UK - 5 December 2016 - Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announces that Dr Colin Goddard has been appointed as non-executive Chairman, effective January 1st 2017. Dr Colin Goddard joined the board of Mission Therapeutics as a...
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

+44 (0)1223 497 454